Most launch teams spend the majority of their measurement budget on reach. Yet reach tells you almost nothing about whether your launch will actually grow.
So which KPIs separate launches that stagnate from those that accelerate, and which ones are simply vanity metrics?
This short video is taken from a recent CELforPharma webinar on omnichannel launch excellence, featuring faculty expert Ben Harbour, VP Global Accounts at Across Health and expert trainer of CELforPharma's Omnichannel Launch Excellence for Medical & Marketing course. In this clip, he walks through a simple but powerful way to think about launch KPIs: a four-part matrix that shows which launch metrics teams tend to over-invest in, and which ones actually predict commercial success. It is a practical model for any Medical, Commercial or Launch Excellence professional who needs to decide what to start measuring, what to stop, and what to continue.
Before you choose your KPIs, you need a clear campaign framework. Ben shows a simple six-step approach to building a launch campaign:
This video focuses on step six: the KPIs.
The framework is a simple matrix. It looks at whether a KPI is quantitative or qualitative, and whether it measures a channel and content or the brand. Read together, the four quadrants move from leading indicators (early signals) to lagging indicators (final results).
The logic is a sequence. First, did we reach people? Then, did they value the experience? Then, will it change their behaviour And finally, did it move the market?
Reach KPIs are quantitative, channel-level metrics that tell you whether you connected with your audience (For example, how many physicians attended your launch webinar).
This is where biopharma spends most of its measurement budget: dashboards that aggregate CRM, email, web and call data. That data is valuable, but it is only a small part of the picture, and it is expensive to maintain. On their own, reach metrics are essentially vanity metrics: they show activity, not impact.
Engagement KPIs are qualitative metrics on how customers experience your channels and content: perception of the channel, perception of the content, ease of use, and whether they valued the experience.
A thousand people attending your launch symposium means little if none of them found it useful. Yet very few companies measure engagement systematically. Most rely on occasional pre- and post-event surveys. A common cause is that Medical and Commercial work in silos and do not share data, so no team ever sees the full qualitative picture. This is one of the most consistently missed KPIs across the pharma industry.
Conversion KPIs are qualitative, brand-level metrics that signal whether engagement will change clinical behaviour, such as brand attribute perception, intent to prescribe, and brand NPS.
The question here is simple: will HCPs apply what they learned — from the symposium, the webinar, the MSL visit or the rep visit — to their clinical practice? These metrics are rarely measured with the frequency and rigour needed to drive action. Yet they are powerful: the drivers behind your brand NPS will often tell you whether you are leading or lagging long before the sales data does.
Effectiveness KPIs are quantitative, brand-level results: market share, share of voice and actual prescription data.
This is the bottom line — the measure of how much difference your launch made. Most pharma teams have good access to sales and market share data, so coverage here is at least partial. What remains harder to capture is the "red thread" that ties everything together: return on investment and true cost-to-serve still stay out of reach for many teams.
Reach is easy to measure, so it gets measured the most… but it is the weakest signal of launch success. The metrics that actually predict growth, engagement quality and conversion intent, are the ones most teams measure least.
Reach tells you that you showed up. Engagement and conversion tell you whether your launch will grow. Build your KPI framework around all four.
A launch KPI framework is a structured way to choose and organise the metrics used to measure a product launch. The model shown by Ben Harbour groups KPIs into four types: reach, engagement, conversion and effectiveness; ranging from early leading indicators to final lagging results.
Leading KPIs (reach and engagement) are early signals you can act on during the launch. Lagging KPIs (conversion and effectiveness) confirm the final commercial result, such as market share and prescriptions. Leading KPIs let you adjust before the lagging numbers are set.
Vanity metrics are reach numbers (e.g., webinar attendance, email opens, web visits) that show activity but not impact. They are valuable for context but, on their own, do not tell you whether a launch will grow.
Because they are qualitative and harder to capture, and because Medical and Commercial teams frequently work in silos and do not share their data. Many companies measure engagement only through occasional surveys, so no one ever sees the complete picture.
Continue your learning from Ben
If you’d like to learn more from Ben, CELforPharma also offers a 1-day, hands-on course where you'll learn to:
Don’t miss the latest insights from our expert faculty
Subscribe to our newsletter to: